Triveni Bio
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $115.0Mattributed |
|---|---|
| Latest round | series-b, $115.0M, 2024-09-01attributed |
| Founded | unknown |
| Headquarters | Watertown MA |
| Industry | biotech|immunology|therapeutics |
| Stage | series-b+ |
| Website | trivenibio.com |
Triveni Bio develops RNA medicines for cardiovascular and metabolic diseases, focusing on targets validated by human genetics. Its platform selects natural RNA mechanisms—antisense, siRNA, or saRNA—based on what each biology requires rather than applying a single modality to every program.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-09-01 | series-b | $115.0M | undisclosed |
Detected tech stack
Google Cloud CDN, OpenResty, Google Cloud, Nginx
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $115.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $115.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | trivenibio.com, read 2026-05-07 |
| Description | self-reported | trivenibio.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.